Literature DB >> 17686865

Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.

Melissa E Laird1, Ronald C Desrosiers.   

Abstract

A FLAG epitope tag was substituted within variable loop 1 (V1), 2 (V2), or 4 (V4) of the gp120 envelope glycoprotein of simian immunodeficiency virus strain 239 (SIV239) to evaluate the extent to which each variable loop may serve as a target for antibody-mediated neutralization. Two sites within each variable loop of SIV239 were chosen for individual epitope tag insertions. FLAG epitope substitutions were also made in the V1, V2, and V4 loops of a neutralization-sensitive derivative of SIV239, SIV316. Of the 10 FLAG-tagged recombinant viruses analyzed, three (SIV239FV1b, SIV239FV2b, and SIV239FV4a) replicated with kinetics similar to those of the parental strain, SIV239, in both CEMx174 cells and the immortalized rhesus monkey T-cell line 221. The SIV316FV1b and SIV316FV4a FLAG variants replicated with a substantial lag, and the five remaining recombinants did not replicate detectably. Both gp160 and gp120 from replication-competent FLAG variants could be immunoprecipitated from transfected 293T cells by the anti-gp120 rhesus monoclonal antibody (RhMAb) 3.11H, the anti-FLAG MAb M2, and CD4-immunoglobulin, whereas only unprocessed gp160 was detected in 293T cells transfected with replication-defective variants. Furthermore, gp120 was detectably incorporated only into virions that were infectious. SIV239FV1b was sensitive to neutralization by MAb M2, with a 50% inhibitory concentration of 1 mug/ml. Neither SIV239FV2b nor SIV239FV4a was sensitive to M2 neutralization. The ability of the M2 antibody to neutralize SIV239FV1b infectivity was associated with an increased ability of the M2 antibody to detect native, oligomeric SIV239FV1b envelope protein on the surfaces of cells relative to that for the other SIV FLAG variants. Furthermore, SIV239FV1b was globally more sensitive to antibody-mediated neutralization than was parental SIV239 when these strains were screened with a panel of anti-SIV MAbs of various specificities. These results indicate that the V1 loop can serve as an effective target for neutralization on SIV239FV1b. However, antibody-mediated neutralization of this variant, similar to that of other SIV239 variants that have been studied previously, was associated with a global increase in neutralization sensitivity. These results suggest that the variable loops on the neutralization-resistant SIV239 strain are difficult for antibodies to access effectively and that mutations that allow neutralization have global effects on the trimeric envelope glycoprotein structure and accessibility.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686865      PMCID: PMC2045528          DOI: 10.1128/JVI.00831-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Retrieval and on-the-fly alignment of sequence fragments from the HIV database.

Authors:  B Gaschen; C Kuiken; B Korber; B Foley
Journal:  Bioinformatics       Date:  2001-05       Impact factor: 6.937

5.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.

Authors:  Eloísa Yuste; Welkin Johnson; George N Pavlakis; Ronald C Desrosiers
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks.

Authors:  W Resch; N Hoffman; R Swanstrom
Journal:  Virology       Date:  2001-09-15       Impact factor: 3.616

8.  Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Authors:  Sang-Moo Kang; Fu Shi Quan; Chunzi Huang; Lizheng Guo; Ling Ye; Chinglai Yang; Richard W Compans
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

9.  A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.

Authors:  Welkin E Johnson; Jennifer Morgan; Julie Reitter; Bridget A Puffer; Susan Czajak; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Structure of an unliganded simian immunodeficiency virus gp120 core.

Authors:  Bing Chen; Erik M Vogan; Haiyun Gong; John J Skehel; Don C Wiley; Stephen C Harrison
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

View more
  7 in total

Review 1.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

2.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

3.  Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.

Authors:  Aaron Wallace; Leonidas Stamatatos
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

4.  The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions.

Authors:  Ralph Pantophlet; Meng Wang; Rowena O Aguilar-Sino; Dennis R Burton
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

5.  HIV-host interactome revealed directly from infected cells.

Authors:  Yang Luo; Erica Y Jacobs; Todd M Greco; Kevin D Mohammed; Tommy Tong; Sarah Keegan; James M Binley; Ileana M Cristea; David Fenyö; Michael P Rout; Brian T Chait; Mark A Muesing
Journal:  Nat Microbiol       Date:  2016-05-23       Impact factor: 17.745

6.  Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries.

Authors:  Seung Yub Han; Alesia Antoine; David Howard; Bryant Chang; Woo Sung Chang; Matthew Slein; Gintaras Deikus; Sofia Kossida; Patrice Duroux; Marie-Paule Lefranc; Robert P Sebra; Melissa L Smith; Ismael Ben F Fofana
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

7.  Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.

Authors:  Vasil B Krapchev; Malgorzata Rychłowska; Alicja Chmielewska; Karolina Zimmer; Arvind H Patel; Krystyna Bieńkowska-Szewczyk
Journal:  Virology       Date:  2018-04-06       Impact factor: 3.616

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.